Common questions about actHIB (FAQ)
Q: What kind of disease is the actHIB vaccine intended to prevent?
actHIB is a vaccine used to reduce the risk of severe, life-threatening infections caused by the Haemophilus influenzae type b (Hib) bacteria. These infections may manifest as several severe illnesses, such as meningitis, pneumonia, and bloodstream infections (septicemia).
Q: Is it true that ActHIB helps prevent bacterial meningitis?
Infections with the target Hib bacteria are known to be a cause of severe, life-threatening illnesses, including bacterial meningitis. Official sources indicate that by stimulating protection against the Hib infection, the vaccine is authorized for the reduction of risk of this type of severe illness.
Q: Is it acceptable to receive actHIB at the same time as other routine childhood vaccines?
Official guidance indicates that actHIB may be co-administered (given at the same visit) with other routine childhood vaccines. The procedure requires that it is administered at a separate anatomical site (e.g., a different limb), and not mixed in the same syringe.
Q: Can different brands of Hib vaccines be used interchangeably during the primary series?
While regulatory guidelines generally state it is preferable to use the same Hib product for all doses in the primary series, official guidance indicates that using different Hib products is permissible if the original product is unavailable or unknown. This is based on established public health guidelines for interchangeability.
Q: What is the process for reporting a possible adverse reaction to actHIB?
Adverse events following vaccination are reported to the national warning system that tracks vaccine safety. In the United States, this system is the Vaccine Adverse Event Reporting System (VAERS), which is jointly managed by the Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA).
Q: Are there any special medical conditions that would make an older child or adult eligible for actHIB?
Yes, although the vaccine is primarily for children up to 5 years old, official recommendations state that Hib vaccination may be indicated for certain older children and adults. This generally applies to individuals with specific medical conditions, such as functional or anatomic asplenia (conditions involving the spleen) or those who have undergone a hematopoietic stem cell transplant.
Q: Can ActHIB be safely given if a child has a minor illness like a cold?
Official public health guidelines generally indicate that individuals with minor illnesses, such as a common cold without fever, are not typically required to postpone vaccination. Healthcare providers usually postpone vaccination only if the child is determined to be moderately or severely ill.
Q: What are the ingredients, other than the active component, found in actHIB?
The official product information states that ActHIB is supplied as a powder and is reconstituted with a saline (salt solution) diluent. Non-active ingredients listed include substances such as sodium chloride, sucrose, and trometamol.
Q: Are there any concerns about giving actHIB to children with a history of seizures?
Regulatory safety data notes that convulsions (with or without fever) have been reported rarely after vaccination. Official guidance states that the management of subsequent vaccination for a child with a history of seizures is subject to careful medical evaluation by a healthcare provider.
Q: If a child misses a dose of actHIB, is it necessary to restart the entire vaccine series?
No. Official public health guidance clarifies that vaccine series generally do not need to be restarted if there is an extended interval between doses. The series is typically resumed and completed based on the child’s current age and the remaining recommended schedule.
Q: What is the general expectation for how long immunity from actHIB lasts?
Studies and official information indicate that a robust immune response has been shown to persist for many years following the completion of the recommended primary series and booster dose. Protection is generally considered long-term for healthy individuals who complete the full schedule.
Q: Does the product contain any preservatives or stabilizers like sucrose?
Yes. The official ingredients list for actHIB includes sucrose, which is a carbohydrate that functions as a stabilizer to help maintain the quality and integrity of the vaccine components.
Q: What is the guidance for patients who receive a bone marrow transplant regarding actHIB?
Public health bodies generally describe Hib vaccination as being indicated for individuals—both children and adults—who have undergone a hematopoietic stem cell transplant (bone marrow transplant). This applies regardless of their prior vaccination status.
Q: Does ActHIB provide protection against all strains of Haemophilus influenzae?
No. The vaccine is specifically designed to target the risk of infection caused by only one particular type of the bacteria, known as Haemophilus influenzae type b (Hib). It does not provide protection against other, non-type b strains of the H. influenzae bacteria.
Q: Does actHIB contain any formaldehyde, as mentioned in some component lists?
Yes, official regulatory documents indicate that the product contains trace amounts of formaldehyde. This substance is used in the manufacturing process and is generally present only in trace amounts.
Q: What does it mean if the injection site reacts with hardening of the skin after actHIB?
Official documents list induration, or hardening of the skin, at the injection site as a reaction that is commonly reported following administration. This effect is described as a short-lived, transient local reaction.
Q: What should parents do at home to help a child who is irritable after the actHIB shot?
Common effects such as pain or fever may cause temporary irritability. For managing pain or fever, official guidance recommends that parents consult with a healthcare provider regarding the possible administration of acetaminophen or ibuprofen.
Q: What general advice is given about monitoring a child after they receive actHIB?
Public health guidance indicates that parents are encouraged to report any side effects to their healthcare provider and to ensure that scheduled follow-up appointments are kept. Parents are also advised to seek immediate medical attention if the child shows signs of a serious allergic reaction.
